Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Earnings Preview: Tellabs Inc.
Tellabs Inc. ( TLAB - Analyst Report ) is slated to release its third-quarter 2012 results on Wednesday, October 24, after the closing bell. The current Zacks Consensus Estimate for the third quarter stands at break even, representing a growth of 66.67% from the year-ago quarter.
With respect to earnings surprise, Tellabs has outperformed the Zacks Consensus Estimate in three out of the last four quarters with an average beat of 66.67%.
Second-Quarter Performance
On July 26, 2012, TLAB declared its financial results for the second quarter of fiscal 2012 beating the Zacks Consensus Estimates. Quarterly GAAP net loss was approximately $5.0 million or 1 cent per share compared with a net loss of $29.0 million or 8 cents per share in the year-ago quarter. Second-quarter 2012 earnings per share came at break even, which was better than the Zacks Consensus Estimate by a penny.
Net revenue in the reported quarter was $288.1 million, down 9% year over year and exactly in line with the Zacks Consensus Estimate. All the four reporting segments of Tellabs witnessed declines in year-over-year sales.
Gross margin in the reported quarter was 39.6% compared with 36.4% in the year-ago quarter. Operating expenses, in the second quarter, were $112.6 million compared with $150.4 million in the prior-year quarter.
Agreement of Estimate Revisions
In the last 30 days, out of 6 estimates there were no estimate revisions in either direction for the third and fourth quarter of 2012. Likewise, out of 6 estimates there were no revisions in either direction for 2012 and 2013 over the same time frame.
Magnitude of Estimate Revisions
Over the last 30 days, the Zacks Consensus Estimates have remained unchanged for the third and fourth quarter of 2012. Similarly, the estimates haven’t moved in either direction for 2012 and 2013.
Our Take
Tellabs is aggressively targeting the booming mobile Internet markets since its legacy switching products are losing relevance. We believe, management’s strategic decision to thoroughly restructure its business model by emphasizing on mobile backhaul solution, IP-packet optical solution coupled with its massive headcount reduction and consolidation of research and development facilities will lead to further improvement in margins going forward. However, our major concern for Tellabs is the increasing competition in its core wireless backhaul solutions segment. The company has already lost a significant amount of business from its most important customer AT&T Inc. ( T - Analyst Report ) , which could have severe consequences on Tellabs’ financial condition in 2012.
We are maintaining our long-term Neutral recommendation on Tellabs. The company also holds a Zacks #3 Rank, implying a short-term Hold rating on the stock.
Read the full reports :
Analyst Report on T
Analyst Report on TLAB